Suppr超能文献

人乳头瘤病毒诱导疾病的免疫疗法。

Immunotherapy of human papilloma virus induced disease.

作者信息

van der Burg Sjoerd H

机构信息

Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.

出版信息

Open Virol J. 2012;6:257-63. doi: 10.2174/1874357901206010257. Epub 2012 Dec 28.

Abstract

Immunotherapy is the generic name for treatment modalities aiming to reinforce the immune system against diseases in which the immune system plays a role. The design of an optimal immunotherapeutic treatment against chronic viruses and associated diseases requires a detailed understanding of the interactions between the target virus and its host, in order to define the specific strategies that may have the best chance to deliver success at each stage of disease. Recently, a first series of successes was reported for the immunotherapy of Human Papilloma Virus (HPV)-induced premalignant diseases but there is definitely room for improvement. Here I discuss a number of topics that in my opinion require more study as the answers to these questions allows us to better understand the underlying mechanisms of disease and as such to tailor treatment.

摘要

免疫疗法是旨在增强免疫系统抵抗免疫系统起作用的疾病的治疗方式的统称。针对慢性病毒及相关疾病设计最佳免疫治疗方案,需要详细了解目标病毒与其宿主之间的相互作用,以便确定在疾病的每个阶段最有可能取得成功的具体策略。最近,人乳头瘤病毒(HPV)诱发的癌前疾病免疫疗法取得了首批系列成功案例,但仍有很大的改进空间。在此,我讨论一些我认为需要更多研究的主题,因为对这些问题的回答能让我们更好地理解疾病的潜在机制,从而量身定制治疗方案。

相似文献

1
Immunotherapy of human papilloma virus induced disease.
Open Virol J. 2012;6:257-63. doi: 10.2174/1874357901206010257. Epub 2012 Dec 28.
3
Immunotherapy against cancer-related viruses.
Cell Res. 2017 Jan;27(1):59-73. doi: 10.1038/cr.2016.153. Epub 2016 Dec 23.
6
Targeting HPV in gynaecological cancers - Current status, ongoing challenges and future directions.
Womens Health (Lond). 2020 Jan-Dec;16:1745506520961709. doi: 10.1177/1745506520961709.
8
Host immune responses to cervical cancer.
Curr Opin Obstet Gynecol. 2009 Feb;21(1):54-9. doi: 10.1097/GCO.0b013e32831a9890.

引用本文的文献

1
Viral Modulation of TLRs and Cytokines and the Related Immunotherapies for HPV-Associated Cancers.
J Immunol Res. 2018 May 2;2018:2912671. doi: 10.1155/2018/2912671. eCollection 2018.
3
Tailored immunotherapy for HPV positive head and neck squamous cell cancer.
Oral Oncol. 2014 Sep;50(9):780-4. doi: 10.1016/j.oraloncology.2013.09.010. Epub 2013 Oct 11.

本文引用的文献

1
Differential macrophage programming in the tumor microenvironment.
Trends Immunol. 2012 Mar;33(3):119-26. doi: 10.1016/j.it.2011.12.001. Epub 2012 Jan 23.
2
Expanding roles for CD4⁺ T cells in immunity to viruses.
Nat Rev Immunol. 2012 Jan 20;12(2):136-48. doi: 10.1038/nri3152.
3
Infiltrating lymphocytes and human papillomavirus-16--associated oropharyngeal cancer.
Laryngoscope. 2012 Jan;122(1):121-7. doi: 10.1002/lary.22133.
4
Identification and manipulation of tumor associated macrophages in human cancers.
J Transl Med. 2011 Dec 16;9:216. doi: 10.1186/1479-5876-9-216.
5
Host-derived MCP-1 and MIP-1α regulate protective anti-tumor immunity to localized and metastatic B16 melanoma.
Am J Pathol. 2012 Jan;180(1):365-74. doi: 10.1016/j.ajpath.2011.09.005. Epub 2011 Oct 26.
6
Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer.
Int J Cancer. 2012 Jul 15;131(2):E74-85. doi: 10.1002/ijc.26497. Epub 2011 Nov 19.
8
Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients.
Int J Cancer. 2012 Aug 15;131(4):864-73. doi: 10.1002/ijc.26457. Epub 2011 Nov 8.
9
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.
J Exp Med. 2011 Sep 26;208(10):1949-62. doi: 10.1084/jem.20101956. Epub 2011 Sep 19.
10
CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend.
Cancer Immunol Immunother. 2012 Jan;61(1):63-70. doi: 10.1007/s00262-011-1092-5. Epub 2011 Aug 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验